author-photo

Maria Rosario

Takeda Pharmaceutical Company

48

Papers

2870

Citations

Citation Trend

Filter By

Papers (37) Sort By

Journal Conference Others

Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease

2021 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D 2/D 3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

2021
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.

2021 Aaps Journal
Show All
- Source
- Cite
- Save
Citations (2)
Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease.

2021 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (0)
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis.

2020 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (6)
P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease

2020 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (1)
DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2

2020 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (0)
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study

2020 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (7)
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease.

2020 Intestinal Research
Show All
- Source
- Cite
- Save
Citations (4)
P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

2019 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (0)